https://www.selleckchem.com/pr....oducts/tucidinostat-
No DLTs occurred, and MTD was DL 2. Most common toxicities with TVEC were fever ( = 8), chills ( = 3), hematomas ( = 3), and injection site pain ( = 3). Thromboembolic events ( = 2) and bradycardia ( = 1) occurred during or after NAC. Five patients (55%) achieved RCB0, 2 had RCB1 (22%), and 2 had RCB2 (22%). The addition of TVEC to NAC was feasible at the approved dose, with manageable toxicity. The complete response rate was 55%. The addition of TVEC to NAC was feasible at the approved dose, with manageable toxicity. The
Like
Comment
Share
